Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Chronic Prostatitis/Chronic Pelvic Pain SyndromeÀ» °¡Áø ûÀå³â ȯÀڵ鿡 ´ëÇÑ ¾ËǪÁ¶½ÅÀÇ Ä¡·áÈ¿°ú The Efficacy of Alfuzosin for Chronic Prostatitis/ Chronic Pelvic Pain Syndrome in Young and Middle Aged Patients

´ëÇѺñ´¢±â°úÇÐȸÁö 2007³â 48±Ç 8È£ p.858 ~ 862
À¯¿µ±Ù, ±èÇüÁö, ¹ÚÈïÀç,
¼Ò¼Ó »ó¼¼Á¤º¸
À¯¿µ±Ù ( Ryu Young-Geun ) 
´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

±èÇüÁö ( Kim Hyung-Jee ) 
´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
¹ÚÈïÀç ( Park Heung-Jae ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract


Purpose: Many studies about efficacy of alpha blocker to Chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) have shown variable results. The aim of this study was to confirm the efficacy of alpha blocker in young and middle aged patients with CP/CPPS to exclude the effect of benign prostatic hyperplasia.

Materials and Methods: Fifty seven men with CP/CPPS were randomized in a single-blind fashion, to receive either; tosufloxacin(450mg/d)(group 1; 15 patients), or; tosufloxacin(450mg/d) and alfuzosin(10mg/d)(group 2; 42 patients) for 2 months. The NIH chronic prostatitis symptom index (NIH-CPSI), International Prostate Symptom Score(IPSS) and International Index of Erectile Function-5(IIEF-5) were used to grade the symptoms and the quality of life(QoL) impact at the start and 1 and 2 months into the study.

Results: There was no significant difference between group 1 and group 2 in relation to age, duration and sub-factor scores of IPSS, NIH-CPSI and IIEF-5 at the baseline. No statistically significant difference in the NIH- CPSI total score was seen, but the urinary and QoL factors in group 2 showed greater improvement. A statistically significant difference was seen in the IPSS total score, especially, obstructive factor in group 2 showed greater improvement. The IIEF-5 total score was seen more increase, but it wasn¡¯t significant.

Conclusions: The efficacy of alfuzosin demonstrated improvements in the NIH-CPSI(this was not significant.) and IPSS total score. Especially voiding factors were significantly improved in relation to the NIH-CPSI and IPSS scores in the alfuzosin treatment group.

Å°¿öµå

Prostate; Alpha blocker; Pain

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS